Paul E. Wakely

217 papers receiving 4.8k citations

Paul E. Wakely's Hit Papers

Phase II Trial of Sorafenib in Metastatic Thyroid Cancer 2009 · 443 citations
4430+5+11Years since publication100200300400

Peers

Paul E. Wakely
Comparison fields: 5 of 94
  • Otorhinolaryngology 346
  • Endocrinology, Diabetes and Metabolism 946
  • Rheumatology 833
  • Pulmonary and Respiratory Medicine 1.4k
  • Pathology and Forensic Medicine 732
Replace Edward B. Stelow with:
Edward B. Stelow United States
Paolo Gattuso United States
Alfred Beham Austria
CDM Fletcher United States
Louis H. Weiland United States
R. V. P. Hutter United States
Douglas R. Gnepp United States
Akitaka Nonomura Japan
Thom R. Loree United States
David C. Chhieng United States
Paul E. Wakely relative to Edward B. Stelow United States Edward B. Stelow's profile →
Citations per field
00.5×1.5×2.1×
Edward B. Stelow · 1×
Citations per year

Countries citing papers authored by Paul E. Wakely

Since Specialization
Citations

This map shows the geographic impact of Paul E. Wakely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul E. Wakely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul E. Wakely more than expected).

Fields of papers citing papers by Paul E. Wakely

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul E. Wakely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul E. Wakely. The network helps show where Paul E. Wakely may publish in the future.

Co-authors

The 25 scholars most cited alongside Paul E. Wakely, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul E. Wakely Line = papers co-authored together Paul E. Wakely links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 228 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Hit paper breakdown →
2009443
2 2010313
3 2012298
4 2006157
5 2003156
6 1987102
7 1995100
8 201188
9 200079
10 201372
11 198870
12 200066
13 200953
14 200650
15 199148
16 201547
17 201747
18 199146
19 199645
20 200744

About Paul E. Wakely

Paul E. Wakely is a scholar working on Pulmonary and Respiratory Medicine, Surgery, Oncology, Rheumatology and Pathology and Forensic Medicine, having authored 228 papers that have together received 5.1k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (43 papers), Salivary Gland Tumors Diagnosis and Treatment (26 papers), Lymphoma Diagnosis and Treatment (23 papers), Soft tissue tumor case studies (20 papers), Bone Tumor Diagnosis and Treatments (19 papers), Vascular Tumors and Angiosarcomas (17 papers), Thyroid Cancer Diagnosis and Treatment (13 papers) and Neuroblastoma Research and Treatments (11 papers). The work is most often cited by research in Otorhinolaryngology (346 citations), Endocrinology, Diabetes and Metabolism (946 citations), Rheumatology (833 citations), Pulmonary and Respiratory Medicine (1.4k citations) and Pathology and Forensic Medicine (732 citations). Paul E. Wakely has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include William J. Frable, Joel Mayerson, Syed Z. Ali, Saul Suster, Jeffrey S. Kneisl, Matthew D. Ringel, Motoyasu Saji, Nathan C. Hall, Richard T. Kloos and Jan F. Silverman. Their work appears in journals such as Cancer Cytopathology, Cancer, Diagnostic Cytopathology, American Journal of Clinical Pathology and Human Pathology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact